Potential of peptidergic nootropic therapy in developmental dysphasia in children
Randomized study in people · 2019
- What was studied
- 54 children aged 3–4 with developmental dysphasia
- Main finding
- Randomized comparison with no drug treatment reported speech and parent-questionnaire changes over two months.
Active vocabulary · 2.3-fold increase with Cortexin versus 1.4-fold without medication
Reported findings and study design
Open randomized comparison of 54 children aged 3–4 with developmental dysphasia: 27 received one 10-day intramuscular course, and 27 received no drug. All parents received speech-stimulation guidance. Outcomes were assessed at day 60.
Population or model 54 children aged 3–4 with developmental dysphasia
Dose, route and schedule
One 10-day course of daily intramuscular Cortexin. The article specifies 0.5 mg/kg for children under 20 kg and 10 mg for children over 20 kg. This describes the historical study.
Protocol source ↗ · Original Russian journal methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Active vocabulary | 2.3-fold increase with Cortexin versus 1.4-fold without medication | |
| Spoken phrases | 3.6-fold increase with Cortexin versus 1.5-fold without medication | |
| Adverse events | The authors reported none during treatment in this small study |
Selected language measures from Table 1
| Measure | Day | Cortexin (n = 27) | No medication (n = 27) |
|---|---|---|---|
| Active vocabulary, words | 0 | 13.7 ± 1.8 | 15.4 ± 1.5 |
| Active vocabulary, words | 60 | 31.7 ± 5.6 | 22.0 ± 2.0 |
| Spoken phrases | 0 | 2.0 ± 0.4 | 2.1 ± 0.4 |
| Spoken phrases | 60 | 7.1 ± 1.1 | 3.1 ± 0.5 |
Mean ± standard error as reported. Both groups improved in words and phrases on within-group testing.
The fold changes compare each arm with its own baseline. The open design, lack of placebo, and caregiver-reported measures limit causal inference. Matching arm sizes and selected outcomes suggest overlap with the 2020 report.
Source for these results ↗ · Reviewed 2026-11-10
Study limitations and source details
Study limitations
- No masking described; parental ratings and speech-development advice are relevant co-interventions.
- Pediatric clinical findings do not establish enhancement or safety in healthy adults.
Source details
Original Russian article, methods and selected outcome tables checked.
Sources checked
Citation
Zavadenko NN, Davydova LA, Suvorinova NY, Khondkaryan GS. Potential of peptidergic nootropic therapy in developmental dysphasia in children Zh Nevrol Psikhiatr Im S S Korsakova 119(11):47-53. PMID 31851172
Study source ↗ · DOI 10.17116/jnevro201911911147 · Bibliography entry · Link to this summary